EUVIMEDEUVIMED entdecken
Open Access

RFX1 Regulates Immune Microenvironment and Predicts Immunotherapy Response in Colon Cancer: A Multi-Omics and Clinical Analysis

Zhujiang Dai, Xiaoyong Ge, Wenbo Tang, Chen-Ying Liu, Yun Liu, Zhongchuan Wang

Oncology Research · 2025

DOI: 10.32604/or.2025.068473 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Research, 2025. Verfasst von Zhujiang Dai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200092, China. Hauptthemen laut MEDLINE: Colonic Neoplasms, Tumor Microenvironment, Regulatory Factor X1, Biomarkers, Tumor. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The plastic role of regulatory factor X1 (RFX1) in colon cancer progression and its impact on the tumor microenvironment remain poorly understood. The study aimed to clarify the molecular and clinical role of RFX1 in colon cancer.

Methods

We classified colon cancers into subgroups with high and low RFX1 expression and characterized their immune profiles, mutational profiles, cancer immunotherapy and drug sensitivity. By combining RFX1 expression with persistent tumor mutational burden, we proposed a novel nomogram clinical prediction model and validated its predictive performance, and the correlation between high expression and poor prognosis.

Results

Compared to tumor mutational burden (TMB), persistent tumor mutational burden (pTMB) is an independent predictor of prognosis in patients with colon cancer. The predictive efficacy of the combination of RFX1 expression and pTMB was superior to and sensitive than the combination of RFX1 expression with TMB. Among them, patients in the RFX1high/pTMBhigh subgroup had the worst quality of survival and prognosis, whereas those in the RFX1low/pTMBlow subgroup had a relatively better prognosis (p < 0.0001). Univariate Cox regression revealed a significant association between high RFX1 expression and increased risk in colon cancer patients (Hazard Ratio [HR] = 1.58, 95% Confidence Interval [CI]: 1.10-2.25, p = 0.012), which remained independently predictive in multivariate analysis after covariate adjustment (HR = 1.52, 95% CI: 1.04-2.22, p = 0.031).

Conclusion

A nomogram model based on RFX1 combined with pTMB provides an alternative approach for the diagnosis and treatment of colon cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colonic NeoplasmsTumor MicroenvironmentRegulatory Factor X1Biomarkers, TumorImmunotherapyHumansPrognosisMaleFemaleMiddle AgedAgedMutationNomogramsGene Expression Regulation, NeoplasticMultiomics

Stichwörter der Autor:innen

Colon cancerpan-cancerpersistent tumor mutational burdenregulatory factory X1tumor microenvironment

Substanzen

Regulatory Factor X1RFX1 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Colorectal Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200092, China.
  • Shanghai Colorectal Cancer Research Center, Shanghai, 200092, China.

Zitieren

APA

Dai, Z., Ge, X., Tang, W., Liu, C. Y., Liu, Y., & Wang, Z. (2025). RFX1 Regulates Immune Microenvironment and Predicts Immunotherapy Response in Colon Cancer: A Multi-Omics and Clinical Analysis. Oncology Research. https://doi.org/10.32604/or.2025.068473

Vancouver

Dai Z, Ge X, Tang W, Liu CY, Liu Y, Wang Z. RFX1 Regulates Immune Microenvironment and Predicts Immunotherapy Response in Colon Cancer: A Multi-Omics and Clinical Analysis. Oncology Research. 2025. doi:10.32604/or.2025.068473

BibTeX
@article{Dai2025,
  author = {Dai, Zhujiang and Ge, Xiaoyong and Tang, Wenbo and Liu, Chen-Ying and Liu, Yun and Wang, Zhongchuan},
  title = {RFX1 Regulates Immune Microenvironment and Predicts Immunotherapy Response in Colon Cancer: A Multi-Omics and Clinical Analysis},
  journal = {Oncology Research},
  year = {2025},
  doi = {10.32604/or.2025.068473}
}
Kostenlos starten →